GIPR antagonist/GLP-1Investigational · Phase 3

MariTide

Last updated

GIP receptor antagonist and GLP-1 receptor agonist. Monthly (or less frequent).

MariTide (investigational)·Amgen

Other GLP-1 medicines at sellers we link to

  • Lowest compounded tirzepatide on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest compounded semaglutide on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

No seller we link to sells maritide; these are different medicines, compounded and not FDA-approved. Those sellers pay us if you buy, which never changes a price we show.

Catalog reviewed Nov 4, 2026. Feed checks and price reviews are dated separately below. How we verify. Not medical advice.

Data updated . What changed

Average weight lost in its trials

  • Highest dose, monthly (Phase 2)Phase 2 obesity · 52 wks
    −16.2% (nejm.org/doi/full/10.1056/NEJMoa2504214) (-16.2% at 52 wks · Phase 2 obesity · Highest dose, monthly (Phase 2))about 32 lb at 200 lb

Averages from separate trials, so they are not a head-to-head ranking and not a prediction. Pounds apply the percentage to a 200 lb starting weight.

Investigational: not FDA-approved for this or any use. It is still being studied in trials.

Information from FDA labels and published trials, not medical advice.

What to know about MariTide

An ingredient can have several brands, formulations, and approved uses. Prices and trial findings belong to the specific product and dose shown.

Mean weight change in the cited trial
−16.2% (nejm.org/doi/full/10.1056/NEJMoa2504214) (-16.2% at 52 wks · Phase 2 obesity · Highest dose, monthly (Phase 2))

Phase 2 obesity · Highest dose, monthly (Phase 2)

FDA shortage report
In development

Investigational. Not FDA-approved.

Route & frequency
Monthly (or less frequent)

Trial averages are not personal predictions. Weight-loss, A1c, and side-effect figures may come from different trials, doses, or populations; follow each source for its context.

Indications

Investigational uses

MariTide (investigational)

Obesity; type 2 diabetes (investigational)

An investigational peptide-antibody conjugate that antagonizes the GIP receptor while agonizing the GLP-1 receptor, designed for infrequent (monthly) dosing.

Product labeling

Dosing, warnings & contraindications

Choose the named product and route. These are submitted label records, which may differ from current approved prescribing information. The product links above lead to current prescribing information. Indexed text omits tables and images; always read the full source label.

No approved label (investigational)

MariTide is investigational. See its registered studies below. Search DailyMed (dailymed.nlm.nih.gov).

Source: submitted product labeling via openFDA. A listing does not establish FDA approval and may differ from current approved labeling. Read the current prescribing information and consult a clinician.
Evidence

Clinical trials

29 of 30 registered studies indexed. Showing up to 12 records: posted results first, then late-phase trials. Registry counts are not a measure of evidence quality.

  • Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity (clinicaltrials.gov/study/NCT04478708)
    NCT04478708PHASE1Completed110 enrolled
    Has results
    Primary outcome: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Selected primary outcome

    Results · Nov 14, 2026 UTC

    Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Number · participants · Part A: 150 days; Part B: 207 days; Part C Cohort 12: 193 days; Part C Cohort 13: 207 days

    Analysis population: Full analysis set: all randomized participants who received at least one dose of AMG 133 or placebo.

    Part A SAD Cohort 1 AMG 133
    0 participants (clinicaltrials.gov/study/NCT04478708)

    Overall outcome: 6 Participants (clinicaltrials.gov/study/NCT04478708) analyzed

    Part A SAD Cohort 2 AMG 133
    2 participants (clinicaltrials.gov/study/NCT04478708)

    Overall outcome: 6 Participants (clinicaltrials.gov/study/NCT04478708) analyzed

    Part A SAD Cohort 3 AMG 133
    5 participants (clinicaltrials.gov/study/NCT04478708)

    Overall outcome: 7 Participants (clinicaltrials.gov/study/NCT04478708) analyzed

    Part A SAD Cohort 4 AMG 133
    6 participants (clinicaltrials.gov/study/NCT04478708)

    Overall outcome: 6 Participants (clinicaltrials.gov/study/NCT04478708) analyzed

    Part A SAD Cohort 5 AMG 133
    5 participants (clinicaltrials.gov/study/NCT04478708)

    Overall outcome: 6 Participants (clinicaltrials.gov/study/NCT04478708) analyzed

    Part A SAD Cohort 6 AMG 133
    6 participants (clinicaltrials.gov/study/NCT04478708)

    Overall outcome: 6 Participants (clinicaltrials.gov/study/NCT04478708) analyzed

    Part A SAD SC Placebo (Cohorts 1-5, 11)
    3 participants (clinicaltrials.gov/study/NCT04478708)

    Overall outcome: 12 Participants (clinicaltrials.gov/study/NCT04478708) analyzed

    Part A SAD IV Placebo (Cohort 6)
    1 participants (clinicaltrials.gov/study/NCT04478708)

    Overall outcome: 2 Participants (clinicaltrials.gov/study/NCT04478708) analyzed

    Part B MAD Cohort 7 AMG 133
    6 participants (clinicaltrials.gov/study/NCT04478708)

    Overall outcome: 6 Participants (clinicaltrials.gov/study/NCT04478708) analyzed

    Part B MAD Cohort 8 AMG 133
    6 participants (clinicaltrials.gov/study/NCT04478708)

    Overall outcome: 6 Participants (clinicaltrials.gov/study/NCT04478708) analyzed

    Part B MAD Cohort 9 AMG 133
    8 participants (clinicaltrials.gov/study/NCT04478708)

    Overall outcome: 8 Participants (clinicaltrials.gov/study/NCT04478708) analyzed

    Part B MAD Cohort 10 AMG 133
    8 participants (clinicaltrials.gov/study/NCT04478708)

    Overall outcome: 10 Participants (clinicaltrials.gov/study/NCT04478708) analyzed

    Part B MAD Cohorts 7-9 Placebo
    3 participants (clinicaltrials.gov/study/NCT04478708)

    Overall outcome: 6 Participants (clinicaltrials.gov/study/NCT04478708) analyzed

    Part B MAD Cohort 10 Placebo
    0 participants (clinicaltrials.gov/study/NCT04478708)

    Overall outcome: 3 Participants (clinicaltrials.gov/study/NCT04478708) analyzed

    Part A SAD Cohort 11 AMG 133
    6 participants (clinicaltrials.gov/study/NCT04478708)

    Overall outcome: 6 Participants (clinicaltrials.gov/study/NCT04478708) analyzed

    Part C MAD Cohort 12
    5 participants (clinicaltrials.gov/study/NCT04478708)

    Overall outcome: 6 Participants (clinicaltrials.gov/study/NCT04478708) analyzed

    Part C MAD Cohort 13
    6 participants (clinicaltrials.gov/study/NCT04478708)

    Overall outcome: 8 Participants (clinicaltrials.gov/study/NCT04478708) analyzed

    Outcome definition & treatment groups

    A TEAE was defined as any adverse event (AE) which started on or after the first dose of AMG 133. Clinically significant changes in laboratory safety tests, vital signs and 12-lead electrocardiograms (ECGs) were included as AEs.

    Part A SAD Cohort 1 AMG 133: Participants received a single dose of 21 mg AMG 133 SC.

    Part A SAD Cohort 2 AMG 133: Participants received a single dose of 70 mg AMG 133 SC.

    Part A SAD Cohort 3 AMG 133: Participants received a single dose of 140 mg AMG 133 SC.

    Part A SAD Cohort 4 AMG 133: Participants received a single dose of 280 mg AMG 133 SC.

    Part A SAD Cohort 5 AMG 133: Participants received a single dose of 560 mg AMG 133 SC.

    Part A SAD Cohort 6 AMG 133: Participants received a single dose of 70 mg AMG 133 IV.

    Part A SAD SC Placebo (Cohorts 1-5, 11): Participants received a single dose of placebo SC.

    Part A SAD IV Placebo (Cohort 6): Participants received a single dose of placebo IV.

    Part B MAD Cohort 7 AMG 133: Participants received multiple doses of 140 mg AMG 133 SC Q4W.

    Part B MAD Cohort 8 AMG 133: Participants received multiple doses of 280 mg AMG 133 SC Q4W.

    Part B MAD Cohort 9 AMG 133: Participants received multiple doses of 560 mg AMG 133 SC Q4W.

    Part B MAD Cohort 10 AMG 133: Participants received multiple doses of 560 mg AMG 133 SC Q4W. This cohort included the use of digital health tools.

    Part B MAD Cohorts 7-9 Placebo: Participants received multiple doses of placebo SC Q4W.

    Part B MAD Cohort 10 Placebo: Participants received multiple doses of placebo SC Q4W. This cohort included the use of digital health tools.

    Part A SAD Cohort 11 AMG 133: Participants received a single dose of 840 mg AMG 133 SC.

    Part C MAD Cohort 12: Participants received 2 doses of 70 mg AMG 133 SC QW, then 2 doses of 420 mg AMG 133 SC Q4W.

    Part C MAD Cohort 13: Participants received 4 doses of 70 mg AMG 133 SC QW, then 2 doses of 420 mg AMG 133 SC Q4W.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular… (clinicaltrials.gov/study/NCT07037433)
    NCT07037433PHASE3Active_not_recruiting12,800 enrolled
  • Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (clinicaltrials.gov/study/NCT07037459)
    NCT07037459PHASE3Recruiting5,056 enrolled
  • Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (clinicaltrials.gov/study/NCT06858839)
    NCT06858839PHASE3Active_not_recruiting3,853 enrolled
  • Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION) (clinicaltrials.gov/study/NCT07684235)
    NCT07684235PHASE3Recruiting3,200 enrolled
  • Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are… (clinicaltrials.gov/study/NCT06858878)
    NCT06858878PHASE3Active_not_recruiting1,105 enrolled
  • Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) (clinicaltrials.gov/study/NCT07684144)
    NCT07684144PHASE3Recruiting950 enrolled
  • Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart… (clinicaltrials.gov/study/NCT07575399)
    NCT07575399PHASE3Recruiting300 enrolled
  • Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease (clinicaltrials.gov/study/NCT06987695)
    NCT06987695PHASE3Active_not_recruiting279 enrolled
  • Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP)… (clinicaltrials.gov/study/NCT07226765)
    NCT07226765PHASE3Active_not_recruiting250 enrolled
  • Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy (clinicaltrials.gov/study/NCT07225686)
    NCT07225686PHASE3Active_not_recruiting250 enrolled
  • Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight (clinicaltrials.gov/study/NCT07871409)
    NCT07871409PHASE3Recruiting230 enrolled

Source: ClinicalTrials.gov API v2 (clinicaltrials.gov/search) · as of Nov 17, 2026

All trials on ClinicalTrials.gov (clinicaltrials.gov)
Related

Related GLP-1s to compare

Updated automatically

What changed for MariTide

  • TrialMariTide study now recruiting (was not yet recruiting): Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight (clinicaltrials.gov/study/NCT07871409)
  • TrialNew MariTide study registered: Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple Doses (clinicaltrials.gov/study/NCT07921316)
  • TrialNew MariTide study registered: Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) (clinicaltrials.gov/study/NCT07908316)
  • TrialNew MariTide study registered: Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight (clinicaltrials.gov/study/NCT07871409)
  • TrialNew MariTide study registered: Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Available in the Body After a Single Subcutaneous Dose (clinicaltrials.gov/study/NCT07832799)

Written from each source's own record as it changes. Every change on GLPcompare

ClinicalTrials.gov

What MariTide is studied for

Registered trials of this medicine by condition. A trial shows a question being asked, not that the answer is yes.

From PubMed

Latest MariTide trials and reviews

  • Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial (pubmed.ncbi.nlm.nih.gov/40549887)

    Randomized trial · N Engl J Med · Jun 23, 2025 · Jastreboff AM et al. · cited by 71

Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.

Questions

Common questions about MariTide

How much weight can you lose on MariTide?
In its pivotal trial (Phase 2 obesity), MariTide at Highest dose, monthly (Phase 2) showed a mean body-weight change of -16.2% at 52 wks. This is a trial average; individual results vary. Source (nejm.org)
Is MariTide available yet?
No. MariTide is investigational (Phase 3) and not FDA-approved, so it cannot be prescribed or bought yet.
When will MariTide be FDA approved?
FDA has not approved MariTide, and no public record gives an approval date. It is at this stage: Phase 3. The trial registry lists 11 Phase 3 trials: 0 finished and 11 still running. The sponsor lists the last of those as finishing by September 2030, though a company can file with FDA before every trial ends. Source
Can you buy MariTide?
Not legally: FDA has not approved it, so no pharmacy can fill it. FDA has warned companies selling unapproved GLP-1 drugs labeled for research, and says: "The agency urges consumers not to purchase these products which are of unknown quality and may be harmful to their health." Source (fda.gov)
How much does MariTide cost?
It has no legal price, because it is not approved and nobody can legally sell it. Prices online are for unapproved products of unknown quality. What approved GLP-1s cost is on our price pages. Source
Does insurance cover MariTide?
No. It is not FDA approved, so it is on no plan's list, and an HSA or FSA has nothing legal to pay for. Coverage could only come after an approval. Source
Is there a generic MariTide?
No. It has no approved brand to copy. Anything sold as a generic of it is an unapproved product. Source
What is the MariTide dose?
There is no approved dose, because it has no FDA label. The result we cite was at Highest dose, monthly (Phase 2). We do not publish dosing, units or mixing charts for an unapproved medicine: those charts online describe products FDA warns against.
How does MariTide work?
An investigational peptide-antibody conjugate that antagonizes the GIP receptor while agonizing the GLP-1 receptor, designed for infrequent (monthly) dosing.
Is MariTide a GLP-1?
GIP receptor antagonist and GLP-1 receptor agonist. Source
Who makes MariTide?
Amgen.
Can you join a MariTide trial?
A clinical trial is one legal way to receive a medicine FDA has not approved. ClinicalTrials.gov shows 6 trials recruiting now, with who can enroll and where. Source (clinicaltrials.gov)